Converting Injectable Therapies to Combination Drug-Device Products
Publication
Article
BioPharm InternationalBioPharm International, Partnerships for Outsourcing May 2022
Volume 2022 eBook
Issue 2
Pages: 14–17
The author describes how to seize market opportunities while navigating the requirements of both drug therapies and delivery devices.
M.Dörr & M.Frommherz- Stock.adobe.com
The global biopharma market has experienced a remarkable period of evolution and expansion. In that time, parenteral medications have become one of the industry’s most important innovation and growth drivers.
Fueled by a continuing shift toward at-home, self-administered care—an established trend accelerated by the COVID-19 pandemic—the rapid surge in demand for injectable therapies is set to continue in the coming years. Between 2020 and 2027, sales of parenteral medications are projected to expand from 53–57% of global market volume, with most of those gains taken away from oral drugs (1).
Read this article in BioPharm International's Partnerships for Outsourcing eBook.
About the author
Markus Hörburger is product and service manager Secondary Packaging & Device Assembly at Vetter.
Article details
BioPharm International
eBook: Partnerships for Outsourcing
May 2022
Pages: 14–17
Citation
When referring to this article, please cite it as M. Hörburger, “Converting Injectable Therapies to Combination Drug-Device Products,” BioPharm International Partnerships for Outsourcing eBook (May 2022).
Articles in this issue
Balancing Internal Focus Against External Capabilities
The Essential Ingredient in any Sponsor-CRO Partnership: Trust
Fostering Orphan Drugs
Preparing for the Future: Expanding Capacity and Facilitating Multi-modalities
The CDMO Carousel
What Outsourcing Partners Wish You Knew
Converting Injectable Therapies to Combination Drug-Device Products
Recent Videos
Related Content
Psilera, Hesperos Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025Article
The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.
